+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Drugs for Spinal Muscular Atrophy Market by Product Type, Treatment Type, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The spinal muscular atrophy therapeutics market is rapidly redefining standards of care, blending targeted genetic innovations with evolving commercial frameworks. Senior decision-makers face an increasingly intricate environment shaped by molecular advances, dynamic stakeholder engagement, and complex regulatory and tariff realities.

Market Snapshot: Spinal Muscular Atrophy Therapeutics

Driven by scientific discovery, investment, and policy adaptation, the spinal muscular atrophy therapeutics market has evolved beyond rare pediatric care into a multifaceted ecosystem. Market size and robust CAGR figures underscore high growth potential as gene therapies and small molecules gain traction in both established and emerging regions. Strategic investment and a broadened therapeutic pipeline propel the sector, creating an environment where competition and collaboration intersect.

Scope & Segmentation

This comprehensive report delivers actionable insight into the spinal muscular atrophy therapeutics sector, providing clarity on product innovation, regional dynamics, and patient diversity.

  • Product Types: Antisense oligonucleotides (e.g., nusinersen), gene therapies (such as onasemnogene abeparvovec), and small molecules (including risdiplam).
  • Treatment Approaches: Monotherapy or combination therapy regimens; each with distinct development, scalability, and reimbursement profiles.
  • Distribution Channels: Options include home healthcare, hospital pharmacies for biologics, and specialty clinics delivering multidisciplinary care.
  • Patient Age Groups: Segmentation across adults, children/adolescents, and infants/toddlers, reflecting varied clinical and logistical needs.
  • Regional Coverage: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notably the UK, Germany, France, and major Gulf states), and Asia-Pacific (China, India, Japan, Australia, and Southeast Asian markets).
  • Leading Companies: Astellas Pharma Inc., Biogen Inc., Novartis AG, PTC Therapeutics, Inc., and F. Hoffmann-La Roche Ltd.

Key Takeaways for Decision-Makers

  • Therapeutic innovation is redefining disease management: Gene therapy and antisense oligonucleotides have transitioned from concept to clinical reality, driving broader patient impact and expanding access considerations.
  • The adoption of orally administered small molecules reflects demand for patient convenience and sustained disease control across age groups.
  • Strategic partnerships underpin manufacturing scalability, supply chain resilience, and successful market access amid rising competition.
  • Healthcare payers increasingly seek robust real-world evidence, not only for regulatory approval but also to justify reimbursement and long-term value.
  • Differentiation relies on evidence-based outcomes, patient-centric support models, and agility in responding to changing policy and tariff conditions.

Primary Keyword Focus: Spinal Muscular Atrophy Therapeutics

Evaluating the 2025 US Tariff Impact

The 2025 US tariff measures introduce nuanced cost pressures on manufacturers and distributors of spinal muscular atrophy therapeutics. Increased levies on imported biologic components and packaging materials may drive up production costs. Many market participants are shifting toward localized manufacturing and diversified sourcing, aiming to preserve pricing stability and patient access while adapting to changing import duties. These moves prompt companies to invest in process optimization, automation, and robust supplier networks to maintain their competitive edge. Payers closely monitor these adjustments, demanding substantiation of value as any price changes reach the clinical market.

Methodology & Data Sources

This analysis integrates primary research insights from expert interviews with industry leaders, payers, and advocacy groups. Secondary sources include regulatory databases, peer-reviewed literature, and clinical trial registries. The methodology is anchored by rigorous thematic analysis, data triangulation, and iterative stakeholder validation to ensure credibility and relevance.

Why This Report Matters

  • Enables evidence-based strategic decisions by mapping regulatory, clinical, and market forces across products, regions, and patient segments.
  • Delivers actionable intelligence on emerging reimbursement models, tariff impacts, and competitive positioning—critical for prioritizing innovation and mitigating risk.
  • Equips stakeholders with a multidimensional view necessary for aligning product development and access strategies to diverse healthcare environments.

Conclusion

This report guides senior leaders in navigating the complexities of spinal muscular atrophy therapeutics, highlighting essential drivers for success in a fast-evolving global market. Well-informed strategies foster patient access, operational resilience, and sustainable growth amid continuous scientific and policy change.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Spinal Muscular Atrophy Market, by Product Type
8.1. Introduction
8.2. Antisense Oligonucleotide
8.2.1. Nusinersen
8.3. Gene Therapy
8.3.1. Onasemnogene Abeparvovec
8.4. Small Molecule
8.4.1. Risdiplam
9. Drugs for Spinal Muscular Atrophy Market, by Treatment Type
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Drugs for Spinal Muscular Atrophy Market, by Distribution Channel
10.1. Introduction
10.2. Home Healthcare
10.3. Hospital Pharmacy
10.4. Specialty Clinic
11. Drugs for Spinal Muscular Atrophy Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Child And Adolescent
11.4. Infant And Toddler
12. Americas Drugs for Spinal Muscular Atrophy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drugs for Spinal Muscular Atrophy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drugs for Spinal Muscular Atrophy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Astellas Pharma Inc.
15.3.2. Biogen Inc.
15.3.3. Novartis AG
15.3.4. PTC Therapeutics, Inc.
15.3.5. F. Hoffmann-La Roche Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY NUSINERSEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ONASEMNOGENE ABEPARVOVEC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY RISDIPLAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY CHILD AND ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY INFANT AND TODDLER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 45. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 46. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 47. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 53. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 88. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 89. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 90. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 96. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 109. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 110. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 111. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 116. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 117. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 118. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 144. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 145. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 146. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 158. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 159. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 160. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. QATAR DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 165. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 166. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. FINLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 186. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 187. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. EGYPT DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 191. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 193. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 195. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. TURKEY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 207. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 208. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 209. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. NORWAY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 213. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 214. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 215. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 216. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. POLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 234. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 236. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 237. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 238. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. CHINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 243. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 244. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 245. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. INDIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 250. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 251. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 278. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 279. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Drugs for Spinal Muscular Atrophy market report include:
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.

Related Topics

Related Reports

Spinal Muscular Atrophy Treatment Market by Treatment Type, Patient Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Spinal Muscular Atrophy Treatment Market by Treatment Type, Patient Type, Route of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034 - Product Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Spinal Muscular Atrophy - Global Strategic Business Report - Product Image

Spinal Muscular Atrophy - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Spinal Muscular Atrophy Market Report 2025 - Product Image

Spinal Muscular Atrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.